In many studies, galectin-3 is described as a novel prognostic biomarker with a strong predictive value for cardiovascular mortality and hospital re-admission in heart failure (HF), conditions that are prevalent in patients with OSA [13]. This evidence concerns the gene LGALS3 and heart failure.